On June 4, 2025 TriSalus Life Sciences, Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), which seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, reported the launch of the TriNav FLX Infusion System, the latest addition to the TriNav Portfolio (Press release, TriSalus Life Sciences, JUN 4, 2025, View Source [SID1234653731]). TriNav FLX, with enhanced trackability, significantly expands our existing portfolio of TriNav products, offering Interventional Radiologists enhanced trackability and more options to select the right product for the right patient1.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The TriNav FLX Infusion System retains the same trusted Pressure-Enabled Drug DeliveryTM (PEDDTM) benefits as existing products but introduces an important advancement in design – The new system features twice the length of more flexible material at the distal end, allowing for easier navigation through more tortuous vessels. This enhancement is particularly beneficial for procedures where precise control and flexibility are required due to challenging peripheral vascular anatomy.
Key features of the TriNav FLX Infusion System include:
Enhanced Trackability: The more flexible distal end provides improved navigation through challenging pathways.
Reduction in Force: In benchtop models, the TriNav FLX demonstrated a 28% reduction in force during navigation compared to the standard TriNav design.1
"We’re excited to further expand our TriNav portfolio with the introduction of the TriNav FLX Infusion System," said Mary Szela, CEO of TriSalus Life Sciences. "With TriNav FLX, we now offer a comprehensive suite of advanced technologies designed to support Interventional Radiologists in navigating a wide range of peripheral vessel sizes and complexities. Our continued investment in portfolio innovation underscores our commitment to making Pressure-Enabled Drug Delivery accessible to more patients. Importantly, TriNav FLX is also eligible for reimbursement under HCPCS Code C8004 for simulation—or mapping—as well as C9797 for treatment procedures. This dual coverage allows clinicians to use TriNav FLX for both planning and delivery in radioembolization, supporting greater precision and continuity of care."
For more information about the TriNav Infusion System portfolio, including indications, contraindications, and instructions for use, visit View Source